Results 71 to 80 of about 79,032 (289)

Prophylactic Antiemetic Effects of Midazolam, Ondansetron and their Combination after Middle Ear Surgery

open access: yesمجله دانشکده پزشکی اصفهان, 2016
Background: The purpose of the present study was to evaluate the efficacy of midazolam-ondansetron combination in prevention of postoperative nausea and vomiting (PONV) after middle ear surgery and its comparison with using midazolam or ondansetron alone.
Azim Honarmand   +2 more
doaj  

Drug Monitoring of Therapy with Midazolam in Patients with ARDS: A Single-Center Prospective Study

open access: yesMedicina
Background and Objectives: One of the two primary classes of drugs administered in ICUs for pharmacological sedation is benzodiazepines. Among these, anesthesiologists consider midazolam the most commonly used and clinically significant agent.
Marek Grochla   +3 more
doaj   +1 more source

Acute toxic leucoencephalopathy following protonitazene ingestion

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Distribution of illicit counterfeit alprazolam containing the highly potent synthetic opioid‐receptor agonist protonitazene recently resulted in a number of severe overdoses in Ireland. We report three cases that presented to our hospital, within 6 weeks of one another, following ingestion of illicitly‐sourced alprazolam.
Ruadhan O'Laoi   +5 more
wiley   +1 more source

A comparison of propofol and midazolam/meperidine sedation in upper gastrointestinal endoscopy

open access: yes, 2016
Introduction : There is increasing interest in sedation for upper gastrointestinal endoscopy (UGE). Prospective randomized studies comparing sedation properties and complications of propofol and midazolam/meperidine in upper gastrointestinal endoscopy ...
Dogan Yildirim   +5 more
core   +1 more source

Translational development of crisugabalin for neuropathic pain

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João   +5 more
wiley   +1 more source

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID‐19 and adverse outcomes on prescribing patterns in England remains uncertain.
Alvina Chaudhry   +3 more
wiley   +1 more source

Combining nefazodone and midazolam during ECT

open access: yes, 1999
SummaryWe report the case of a patient suffering from dysthymia. He underwent successful ECT treatment and was medicated with nefazodone and midazolam. Comparing the EEG and motor seizure duration in the periods with and without midazolam, no significant
Z. Al-Dubai   +3 more
core   +1 more source

Predictors of anti-convulsant treatment failure in children presenting with malaria and prolonged seizures in Kampala, Uganda. [PDF]

open access: yes, 2009
BACKGROUND: In endemic areas, falciparum malaria remains the leading cause of seizures in children presenting to emergency departments. In addition, seizures in malaria have been shown to increase morbidity and mortality in these patients. The management
Staedke Sarah G   +14 more
core   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling   +6 more
wiley   +1 more source

Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to describe the pharmacokinetics (PK) of levetiracetam (LEV) in term neonates treated for neonatal seizures secondary to hypoxic–ischemic encephalopathy (HIE). Methods Fifteen neonates were included and received a loading dose ranging from 30 to 60 mg/kg followed by eight maintenance doses corresponding to one‐fourth of the loading
Léo Mimram   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy